Home › Research › Clinical safety
Safety, tolerability and potential biomarkers of vodobatinib in patients with dementia with Lewy bodies
Fernando Pagán, Yasar A. Torres-Yaghi, Michaeline L. Hebron, Barbara Wilmarth, Xiaoguang Liu, Jaeil Ahn, Charbel Moussa. Parkinsonism & Related Disorders, 2025-09-07
Topic: Risk, prevention and care in population studies
Plain-language summary
Twenty-nine individuals were enrolled, 3 were women (10.3 %), age 76.3 ± 6 years (mean ± SD). Vodobatinib was safe and well-tolerated and more adverse events were noted in the placebo (56) vs vodobatinib 192 mg (19) or 384 mg (6) groups. The number of falls were reduced in the vodobatinib 192 mg (6) and 384 mg (0) compared to placebo (28) groups. The only potential significant change in cerebrospinal fluid (CSF) biomarkers was Aβ42/Aβ40 in 192 mg vodobatinib (p = 0.0002) and 384 mg (0.0121) compared to placebo. There was no change in homovanillic acid, a biomarker of dopamine level, or other potential CSF and plasma biomarkers of DLB. Exploratory clinical outcomes were not different between baseline and 3 months in vodobatinib compared to placebo. Vodobatinib appears to be safe and tolerated, but larger trials and longer treatment periods are needed to determine its effects on biomarkers and clinical outcomes.
What this study adds
Evidence grade: High
In this small study of 29 people with dementia with Lewy bodies, vodobatinib was safe and well-tolerated, with reduced falls and a change in one cerebrospinal fluid biomarker compared to placebo. Exploratory clinical outcomes did not differ from placebo, and the authors state that larger trials and longer treatment periods are needed.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Pagán, F., Torres-Yaghi, Y. A., Hebron, M. L., Wilmarth, B., Liu, X., Ahn, J., et al. (2025). Safety, tolerability and potential biomarkers of vodobatinib in patients with dementia with Lewy bodies. Parkinsonism & Related Disorders. https://doi.org/10.1016/j.parkreldis.2025.108020
Vancouver
Pagán F, Torres-Yaghi YA, Hebron ML, Wilmarth B, Liu X, Ahn J, et al. Safety, tolerability and potential biomarkers of vodobatinib in patients with dementia with Lewy bodies. Parkinsonism & Related Disorders. 2025. doi:10.1016/j.parkreldis.2025.108020. PMID: 40939527.
BibTeX
@article{pagan2025-40939527,
author = {Pagán, Fernando and Torres-Yaghi, Yasar A. and Hebron, Michaeline L. and Wilmarth, Barbara and Liu, Xiaoguang and Ahn, Jaeil and Moussa, Charbel},
title = {{Safety, tolerability and potential biomarkers of vodobatinib in patients with dementia with Lewy bodies}},
journal = {Parkinsonism \& Related Disorders},
year = {2025},
doi = {10.1016/j.parkreldis.2025.108020},
pmid = {40939527},
url = {https://doi.org/10.1016/j.parkreldis.2025.108020}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Twenty-nine individuals were enrolled, 3 were women (10.3 %), age 76.3 ± 6 years (mean ± SD).
- Vodobatinib was safe and well-tolerated and more adverse events were noted in the placebo (56) vs vodobatinib 192 mg (19) or 384 mg (6) groups.
- The number of falls were reduced in the vodobatinib 192 mg (6) and 384 mg (0) compared to placebo (28) groups.
- The only potential significant change in cerebrospinal fluid (CSF) biomarkers was Aβ42/Aβ40 in 192 mg vodobatinib (p = 0.0002) and 384 mg (0.0121) compared to placebo.
- There was no change in homovanillic acid, a biomarker of dopamine level, or other potential CSF and plasma biomarkers of DLB.
Why it matters
In this small study of 29 people with dementia with Lewy bodies, vodobatinib was safe and well-tolerated, with reduced falls and a change in one cerebrospinal fluid biomarker compared to placebo. Exploratory clinical outcomes did not differ from placebo, and the authors state that larger trials and longer treatment periods are needed.
Study details
- Evidence strengthHigh
How this study scored 39/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Parkinsonism & Related Disorders) |
| Journal's citation record | 2 / 4 | Parkinsonism & Related Disorders: journal h-index 155 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 2 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 1.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Charbel Moussa: h-index 42 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Georgetown University: institution h-index 824 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40939527) |
| Free to read | 2 / 2 | Free to read |
| Total | 39 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.parkreldis.2025.108020
- PubMed: 40939527
- Original source →
- Free full text: Parkinsonism & Related Disorders →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Clinical safety from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.